TNNI3

Overview

TNNI3 encodes cardiac troponin I (cTnI), a cardiac-specific contractile protein and one of the most widely used biomarkers of myocardial injury in clinical medicine. In the context of biomedical research and diagnostics, TNNI3 is primarily studied as a clinical metric rather than as a therapeutic target: its circulating protein product is measured to assess cardiac muscle damage, especially in acute myocardial infarction and other forms of myocardial injury.

Biologically, cardiac troponin I is part of the troponin regulatory complex in the cardiac sarcomere, where it helps control actin–myosin interaction and calcium-dependent contraction. Because cTnI is highly enriched in cardiac tissue, its release into blood reflects disruption of cardiomyocyte integrity. Recent studies also examine how cTnI behaves relative to cardiac troponin T (cTnT), including the cTnI/cTnT ratio, and how myocardial injury pathways such as calpain activity may alter troponin organization. In applied diagnostics, TNNI3 is a major target for ultrasensitive immunoassays, lateral flow formats, and point-of-care platforms.

Recent Publications Focus

Below is a summary of the newest research publications targeting TNNI3 (sorted by publication date).

• 2026-05-26 — PMID: 42118913
  This study developed a low-background cardiac troponin I detection method using an in situ self-color-changing lateral flow immunoassay enabled by hydrogen peroxide-triggered cerium oxide nanoprobes. The assay was designed for rapid visual readout and achieved a visual limit of detection of 0.8 ng/mL with only 30 seconds of coloration. The work highlights how hydrogen peroxide-responsive nanomaterials can improve point-of-care cTnI testing.

• 2026-05-21 — PMID: 42093395
  Researchers reported an ultrasensitive dynamic light scattering immunosensor for cTnI based on a self-cascading reaction and synergistic amplification strategy using metal-organic framework materials. The platform used self-amplifying Au nanoparticle assembly to enhance signal generation, illustrating a highly sensitive analytical approach for cardiac troponin I detection.

• 2026-05-19 — PMID: 42083727
  This smartphone-based microbubble-linked immunosorbent assay combined classification-regression integrated deep learning with portable quantitative biomarker analysis. The platform achieved a detection limit of approximately 0.0001 ng/mL for both NT-proBNP and cTnI after postprocessing, demonstrating the potential of mobile-device-enabled diagnostics for very low-abundance cardiac biomarkers.

• 2026-05-15 — PMID: 42018377
  In calves with bovine respiratory disease complex, investigators examined the effects of Diclofenac sodium and tilmicosin on cardiac biomarkers. Elevated H-FABP and cTnI levels, particularly in the Diclofenac sodium plus tilmicosin group, suggested early-stage subclinical myocardial injury. This study supports the use of cTnI as a sensitive indicator of cardiac stress in veterinary toxicology and disease monitoring.

• 2026-05-15 — PMID: 41621357
  A sandwich-type electrochemical immunosensing strategy was developed using PtAgCu/MoS2 and hexagonal star-like nitrogen-doped carbon to achieve highly efficient signal enhancement. In this context, cTnI was described as the gold-standard biomarker for acute myocardial infarction, underscoring its continued importance in early diagnosis and clinical management.

• 2026-05-15 — PMID: 41655520
  A DNA-engineered immunosensing platform was applied to ultrasensitive detection of clinical protein biomarkers, including NGAL, interleukin-6, and cTnI. For cTnI, the platform achieved a limit of detection of 2.35 pg/mL, demonstrating strong analytical performance for myocardial infarction-associated biomarker measurement.

• 2026-05-12 — PMID: 42063290
  This work introduced hierarchical mesochannel-confined nanozyme reactors to propel gold amplification immunoassays for point-of-care diagnostics. Using FeMPPt-labeled vertical flow lateral flow immunoassays, the authors reported markedly improved performance for qualitative and quantitative detection of cTnI and alpha-fetoprotein, with detection limits 125/230-fold lower than those of AuNP-labeled assays. The study emphasizes the value of nanozyme-enabled amplification for sensitive biomarker testing.

• 2026-05-05 — PMID: 41739020
  This multicohort and experimental synthesis examined the cTnI/cTnT ratio in myocardial injury. The authors noted that cardiac troponin I and cardiac troponin T are often used interchangeably in clinical practice, but emerging evidence suggests the ratio may differ between acute necrotic injury and chronic or non-necrotic myocardial injury. This work points to possible added interpretive value of comparing cTnI with cardiac troponin T in injury phenotyping.

• 2026-05-01 — PMID: 41765115
  In a study of vandetanib-induced cardiac dysfunction, calpain inhibition was shown to preserve myofilament integrity and prevent disruption of cardiac troponin organization. The findings included altered cTnI and cTnT organization, along with downregulation of key myofilament proteins, while calpain-related interventions such as calpain1 knockdown or overexpression were used to probe mechanism. This work links cTnI structural integrity to drug-induced cardiotoxicity and calpain-mediated myofilament damage.

Background PMIDs

• [PMID 41621357]

Result PMIDs

• [PMID 42018377]
• [PMID 41765115]

Target PMIDs

• [PMID 42118913]
• [PMID 42093395]
• [PMID 42083727]
• [PMID 41655520]
• [PMID 42063290]
• [PMID 41739020]